We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
-16.07%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.14B
AUM Growth
-$212M
Cap. Flow
+$85.4M
Cap. Flow %
7.49%
Top 10 Hldgs %
46.56%
Holding
206
New
51
Increased
51
Reduced
18
Closed
36

Top Buys

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$27.8M
2
HUM icon
Humana
HUM
+$19.1M
3
XLRN
Acceleron Pharma
XLRN
+$15.3M
4
QTNT
Quotient Limited Ordinary Shares
QTNT
+$13.2M
5
MDVN
MEDIVATION, INC.
MDVN
+$12.3M

Top Sells

Rank Stock Value
1
DYAX
DYAX CORPORATION
DYAX
+$68.4M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$12.9M
3
BAX icon
Baxter International
BAX
+$10.1M
4
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$8.54M
5
NVRO
NEVRO CORP.
NVRO
+$8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.87%
2 Consumer Staples 0.6%
3 Consumer Discretionary 0.11%
4 Industrials 0.04%
5 Financials 0.02%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SIOX
51
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$5.57M 0.49%
60,625
-6,250
-9% -$667K
ANTH
52
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$5.4M 0.47%
186,520
+62,500
+50% +$1.7M
MYOK
53
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$5.38M 0.47%
502,894
-9
-0% -$82
ALDX icon
54
Aldeyra Therapeutics
ALDX
$94.1M
$5.2M 0.46%
1,240,458
– –
CELG
55
DELISTED
Celgene Corp
CELG
$5M 0.44%
+50,000
New +$5.15M
NERV icon
56
Minerva Neurosciences
NERV
$259M
$4.98M 0.44%
101,317
– –
ALDR
57
PUT
DELISTED
Alder Biopharmaceuticals
ALDR
$4.9M 0.43%
+200,000
New +$4.63M
ABEO icon
58
Abeona Therapeutics
ABEO
$344M
$4.51M 0.4%
70,515
– –
AMGN icon
59
Amgen
AMGN
$238B
$4.5M 0.39%
30,000
-20,000
-40% -$2.97M
CASC
60
DELISTED
Cascadian Therapeutics, Inc.
CASC
$4.33M 0.38%
569,020
– –
AVXS
61
DELISTED
AveXis, Inc. Common Stock
AVXS
$4.09M 0.36%
+150,000
New +$3.28M
GNCA
62
DELISTED
Genocea Biosciences, Inc.
GNCA
$4M 0.35%
+64,577
New +$2.05M
ASMB icon
63
Assembly Biosciences
ASMB
$721M
$3.99M 0.35%
66,250
– –
ARCT icon
64
Arcturus Therapeutics
ARCT
$450M
$3.9M 0.34%
146,896
– –
SPNC
65
DELISTED
Spectranetics Corp
SPNC
$3.88M 0.34%
267,070
-2,500
-0.9% -$34.6K
ANIP icon
66
ANI Pharmaceuticals
ANIP
$1.71B
$3.84M 0.34%
114,060
+101,260
+791% +$3.43M
NDRM
67
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.81M 0.33%
270,000
– –
IMMU
68
DELISTED
Immunomedics Inc
IMMU
$3.55M 0.31%
1,420,000
+1,220,000
+610% +$2.74M
OTIC
69
DELISTED
Otonomy, Inc.
OTIC
$3.52M 0.31%
235,986
+30,000
+15% +$471K
ZLTQ
70
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
$3.31M 0.29%
+122,000
New +$2.88M
FWP
71
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
$3.17M 0.28%
+26,614
New +$2.98M
OMER icon
72
Omeros
OMER
$1.32B
$3.07M 0.27%
+200,000
New +$2.43M
SUPN icon
73
Supernus Pharmaceuticals
SUPN
$2.61B
$3.05M 0.27%
+200,000
New +$2.61M
WBA
74
DELISTED
Walgreens Boots Alliance
WBA
$2.97M 0.26%
35,292
– –
ACAD icon
75
PUT
Acadia Pharmaceuticals
ACAD
$5.1B
$2.8M 0.25%
+200,000
New +$4.36M
1 2
3
4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q1 2016 Portfolio in Review

As of Q1 2016, Perceptive Advisors held 206 positions worth $1.14B, down 16% from $1.35B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Perceptive Advisors deployed $85.4M of net new capital in Q1 2016, opening 51 new positions and adding to 51 existing holdings. Its largest new stake was Humana: 110,000 shares worth $20.1M.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 89% a quarter earlier, followed by Consumer Staples and Consumer Discretionary.

On the sell side, the largest reduction was Teva Pharmaceuticals, an estimated $12.9M trimmed.

  • Perceptive Advisors's largest Q1 2016 buy was Humana: 110,000 shares worth $20.1M.
  • Perceptive Advisors added most to Sarepta Therapeutics in Q1 2016, an estimated $27.8M increase.
  • Perceptive Advisors's biggest Q1 2016 reduction was Teva Pharmaceuticals, cutting an estimated $12.9M.
  • Perceptive Advisors fully exited DYAX CORPORATION in Q1 2016, selling an estimated $68.4M.
  • Perceptive Advisors's ten largest holdings make up 47% of its $1.14B portfolio in Q1 2016.
  • Perceptive Advisors opened 51 new positions and closed 36 in Q1 2016.
  • Perceptive Advisors's portfolio value fell 16% quarter-over-quarter to $1.14B.

Based on Perceptive Advisors's 13F filing for Q1 2016, filed 16 May 2016.